%PDF-1.4
%
75 0 obj
<>
endobj
72 0 obj
<>
endobj
617 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-02T16:26:33Z
2024-03-28T13:14:28-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T13:14:28-07:00
application/pdf
Heather
201227.dec
uuid:b176df45-1dd1-11b2-0a00-9308278d5b00
uuid:b176df48-1dd1-11b2-0a00-1e0000000000
endstream
endobj
61 0 obj
<>
endobj
62 0 obj
<>
endobj
76 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
25 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
33 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
41 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
49 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
654 0 obj
[659 0 R]
endobj
655 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 576 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(signal. J Exp Med 1993;177:923-35.)Tj
-2.175 -1.25 Td
[(10.)-875 (Kawabe )18 (T)74 (, Naka )18 (T)74 (, )37 (Y)100 (oshida K, et al. )18 (The immune responses in)]TJ
2.175 -1.25 Td
(CD40-deficient mice: impaired immunoglobulin class switching)Tj
0 -1.25 TD
(and germinal center formation. Immunity 1994;1:167-78.)Tj
-2.1381 -1.25 Td
[(1)37 (1.)-875 (Xu J, Foy )18 (TM, Laman JD, et al. Mice deficient for the CD40)]TJ
2.1381 -1.25 Td
(ligand. Immunity 1994;1:423-31.)Tj
-2.175 -1.25 Td
[(12.)-875 (Stout RD, Suttles J. )18 (The many roles of CD40 in cell-mediated)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(inflammatory responses. Immunol )18 (T)70 (oday 1996;17:487-92.)]TJ
-2.175 -1.25 Td
[(13.)-875 (Kiener P)92 (A, Moran-Davis P)111 (, Rankin BM, )18 (W)80 (ahl )55 (AF)80 (, )55 (Aruf)18 (fo )55 (A,)]TJ
0 Tc 2.175 -1.25 Td
(Hollenbaugh D. Stimulation of CD40 with purified soluble gp39)Tj
T*
(induces proinflammatory responses in human monocytes. )Tj
T*
(J Immunol 1995;155:4917-25.)Tj
-2.175 -1.25 Td
[(14.)-875 (Stout RD, Suttles J. )18 (The many roles of CD40 in cell-mediated)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(inflammatory responses. Immunol )18 (T)70 (oday 1996;17:487-92.)]TJ
-2.175 -1.25 Td
[(15.)-875 (Clark EA, Ledbetter JA. How B and )18 (T)-257 (cells talk to each other)55 (.)]TJ
0 Tc 2.175 -1.25 Td
(Nature 1994;367:425-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875 (Durie FH, Foy )18 (TM, Masters SR, Laman JD, Noelle RJ. )18 (The role of)]TJ
0 Tc 2.175 -1.25 Td
[(CD40 in the regulation of humoral and cell-mediated immunity)65 (.)]TJ
0.0072 Tw T*
[(Immunol T)70 (oday )-18 (1994;15:406-1)37 (1.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(17.)-875 (Y)100 (ang )37 (Y)129 (, )18 (W)40 (ilson JM. CD40 ligand-dependent )18 (T)-257 (cell activation:)]TJ
2.175 -1.25 Td
(requirement of B7-CD28 signaling through CD40. Science)Tj
0 Tw T*
(1996;273:1864-7.)Tj
0.0249 Tw -2.175 -1.25 Td
[(18.)-875 (Grewal IS, Flavell RA. )55 (A)-220 (central role of CD40 ligand in the)]TJ
2.175 -1.25 Td
[(regulation of CD4+ )18 (T)92 (-cell responses. Immunol )18 (T)70 (oday 1996;)]TJ
0 Tw T*
(17:410-4.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875 (Hollenbaugh D, Mischel-Petty N, Edwards CP)111 (, et al. Expression of)]TJ
0 Tc 2.175 -1.25 Td
(functional CD40 by vascular endothelial cells. J Exp Med)Tj
0 Tw T*
(1995;182:33-40.)Tj
0.0249 Tw -2.175 -1.25 Td
[(20.)-875 (Mach F)80 (, Sch\366nbeck U, Sukhova GK, et al. Functional CD40 ligand)]TJ
2.175 -1.25 Td
(is expressed on human vascular endothelial cells, smooth muscle)Tj
T*
(cells, and macrophages: implications for CD40-CD40 ligand)Tj
-0.00011 Tc T*
[(signaling in atherosclerosis. Proc Natl )55 (Acad Sci USA)]TJ
0 Tc 0 Tw T*
(1997;94:1931-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875 (Karmann K, Hughes CCW)92 (, Schechner J, Fanslow )18 (WC, Pober JS.)]TJ
0 Tc 2.175 -1.25 Td
(CD40 on endothelial cells: inducibility by cytokines and functional)Tj
T*
[(regulation of adhesion molecule expression. Proc Natl )55 (Acad Sci)]TJ
-0.00011 Tc 0 Tw T*
[(USA)-220 (1995;92:4342-6.)]TJ
0 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875 (Y)100 (ellin MJ, Brett J, Baum D, et al. Functional interactions of )18 (T)-257 (cells)]TJ
2.175 -1.25 Td
(with endothelial cells: the role of CD40-CD40-L-mediated signal. )Tj
T*
(J Exp Med 1995;182:1857-64.)Tj
-2.175 -1.25 Td
[(23.)-875 (D\351chanet J, Grosset C, )18 (T)70 (aupin J, et al. CD40 ligand stimulates)]TJ
2.175 -1.25 Td
(proinflammatory cytokine production by human endothelial cells. )Tj
T*
(J Immunol 1997;159:5640-7.)Tj
-2.175 -1.25 Td
[(24.)-875 (Miller DL, )37 (Y)100 (aron R, )37 (Y)100 (ellin MJ. CD40L-CD40 interactions regulate)]TJ
2.175 -1.25 Td
(endothelial cell surface tissue factor and thrombomodulin)Tj
T*
(expression. J Leukocyte Biol 1998;63:373-9.)Tj
-2.175 -1.25 Td
[(25.)-875 (Thomas R, Davis LS, Lipsky PE. Rheumatoid synovium is enriched)]TJ
2.175 -1.25 Td
(in mature antigen-presenting dendritic cells. J Immunol)Tj
0 Tw T*
(1992;152:2613-23.)Tj
0.02499 Tw -2.175 -1.25 Td
[(26.)-875 (Rissoan MC, van Kooten C, Chomarat P)111 (, et al. )18 (The functional)]TJ
2.175 -1.25 Td
(CD40 antigen of fibroblast may contribute to proliferation of)Tj
T*
(rheumatoid synovium. Clin Exp Immunol 1996;104:481-90.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(27.)-875 (Sekine C, )37 (Y)100 (agita H, Miyasaka N, Okumura K. Expression and)]TJ
0 Tc 2.175 -1.25 Td
(function of CD40 in rheumatoid arthritis synovium. J Rheumatol)Tj
0 Tw T*
(1998;25:1048-53.)Tj
0.0249 Tw -2.175 -1.25 Td
[(28.)-875 (MacDonald KP)111 (, Nishioka )37 (Y)129 (, Lipsky PE, )18 (Thomas R. Functional)]TJ
2.175 -1.25 Td
[(CD40 ligand is expressed by )18 (T)-257 (cell in rheumatoid arthritis. J Clin)]TJ
T*
(Invest 1997;100:2404-14.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(29.)-875 (Kyburz D, Corr M, Brinson DC, )18 (V)129 (on Damm )55 (A, )18 (T)35 (ighe H, Carson)]TJ
0 Tc 2.175 -1.25 Td
(DA. Human rheumatoid factor production is dependent on CD40)Tj
T*
[(signaling and autoantigens. J Immunol 1999;163:31)37 (16-22.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(30.)-875 (Durine FH, Fava RA, Foy )18 (TM, )55 (Aruf)18 (fo )55 (A, Ledbetter JA, Noelle RJ.)]TJ
0 Tc 2.175 -1.25 Td
(Prevention of collagen-induced arthritis with an antibody to gp39,)Tj
T*
(the ligand for CD40. Science 1993;261:1328-30.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(31.)-875 (Graf D, M\374ller S, Korth\344uer U, van Kooten C, )18 (W)80 (eise C, Kroczek)]TJ
35.175 80 Td
[(RA. )55 (A)-220 (soluble form of )18 (TRAP)-238 (\(CD40 ligand\) is rapidly released)]TJ
0 Tc T*
[(after )18 (T)-257 (cell activation. Eur J Immunol 1995;25:1749-54.)]TJ
-2.175 -1.25 Td
[(32.)-875 (Pietravalle F)80 (, Lecoanet-Henchoz S, Blasey H, et al. Human native)]TJ
2.175 -1.25 Td
[(soluble CD40L)-238 (is a biologically active trimer)40 (, processed inside)]TJ
T*
(microsomes. J Biol Chem 1996;271:5965-7.)Tj
-2.175 -1.25 Td
[(33.)-875 (Spriggs MK, Fanslow )18 (WC, )55 (Armitage RJ, Belmont J. )18 (The biology of)]TJ
2.175 -1.25 Td
(the human ligand for CD40. J Clin Immunol 1993;13:373-80.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(34.)-875 (Hsu )37 (Y)129 (, Lucci J, Su L, Ehrenfels B, Garber E, )18 (Thomas D.)]TJ
0 Tc 2.175 -1.25 Td
(Heteromultimeric complexes of CD40 ligand are present on the cell)Tj
T*
[(surface of human )18 (T)-257 (lymphocytes. J Biol Chem 1997;272:91)37 (1-5.)]TJ
-2.175 -1.25 Td
[(35.)-875 (Mazzei GJ, Edgerton MD, Losber)18 (ger C, et al. Recombinant soluble)]TJ
2.175 -1.25 Td
(trimeric CD40 ligand is biologically active. J Biol Chem)Tj
0 Tw T*
(1995;270:7025-8.)Tj
0.0249 Tw -2.175 -1.225 Td
[(36.)-875 (W)40 (iley JA, Geha R, Harmsen )55 (AG. Exogenous CD40 ligand induces)]TJ
2.175 -1.225 Td
(a pulmonary inflammation response. J Immunol 1997;158:2932-8.)Tj
-2.175 -1.225 Td
[(37.)-875 (Spriggs MK, )55 (Armitage RJ, Stockbine L, et al. Recombinant human)]TJ
2.175 -1.225 Td
(CD40 ligand stimulates B cell proliferation and immunoglobulin E)Tj
0 -1.225 TD
(secretion. J Exp Med 1992;176:1543-50.)Tj
-2.175 -1.225 Td
[(38.)-875 (Kato K, Santana-Sahag\372n E, Rassenti LZ, et al. )18 (The soluble CD40)]TJ
2.175 -1.225 Td
(ligand sCD154 in systemic lupus erythematosus. J Clin Invest)Tj
0 Tw T*
(1999;104:947-55.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(39.)-875 (Arnett FC, Edworthy SM, Bloch DA, et al. )18 (The )55 (American)]TJ
2.175 -1.225 Td
[(Rheumatism )55 (Association 1987 revised criteria for the classification)]TJ
0 Tc T*
[(of rheumatoid arthritis. )55 (Arthritis Rheum 1988;31:315-24.)]TJ
-0.00011 Tc -0.0298 Tw -2.175 -1.225 Td
[(40.)-875 (V)129 (oskuyl AE, )-55 (Zwinderman AH, )-37 (W)80 (estedt )-55 (ML, )-37 (V)111 (andenbroucke )-55 (JP)111 (,)]TJ
0 Tc 0.0249 Tw 2.175 -1.225 Td
[(Breedeld FC, Hazes JM. )18 (The mortality of rheumatoid vasculitis)]TJ
T*
[(compared with rheumatoid arthritis. )55 (Arthritis Rheum 1996;)]TJ
0 Tw T*
(39:266-71.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(41.)-875 (Hashimoto H, )55 (Abe )18 (T)74 (, Nobunaga M, )37 (Y)100 (oshizawa H, Kyogoku M,)]TJ
0 Tc 2.175 -1.225 Td
[(Mishima )37 (Y)129 (. Proposal of revised criteria for malignant rheumatoid)]TJ
T*
[(arthritis. R)40 (yumachi 1989;29:268-76.)]TJ
-2.175 -1.225 Td
[(42.)-875 (Thomas R, McIlraith M, Davis LS, Lipsky PE. Rheumatoid)]TJ
2.175 -1.225 Td
[(synovium is enriched in CD45RBdim mature memory )18 (T)-257 (cells that)]TJ
T*
[(are potent helpers for B cell dif)18 (ferentiation. )55 (Arthritis Rheum)]TJ
0 Tw T*
(1992;35:1455-65.)Tj
0.02499 Tw -2.175 -1.225 Td
[(43.)-875 (Henn )18 (V)129 (, Slupsky JR, Gr\344fe M, et al. CD40 ligand on activated)]TJ
2.175 -1.225 Td
(platelets triggers an inflammatory reaction of endothelial cells.)Tj
T*
(Nature 1998;391:591-4.)Tj
-2.175 -1.225 Td
[(44.)-875 (Aukrust P)111 (, M\374ller F)80 (, Ueland )18 (T)74 (, et al. Enhanced levels of soluble and)]TJ
2.175 -1.225 Td
(membrane-bound CD40 ligand in patients with unstable angina.)Tj
T*
[(Possible reflection of )18 (T)-257 (lymphocyte and platelet involvement in the)]TJ
T*
(pathogenesis of acute coronary syndromes. Circulation)Tj
0 Tw T*
(1999;100:614-20.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(45.)-875 (V)111 (akkalanka RK, )18 (W)80 (oo C, Kirou KA, Koshy M, Ber)18 (ger D, Crow)]TJ
0 Tc 2.175 -1.225 Td
(MK. Elevated levels and functional capacity of soluble CD40)Tj
T*
[(ligand in systemic lupus erythematosus sera. )55 (Arthritis Rheum)]TJ
0 Tw T*
(1999;42:871-81.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(46.)-1150 (Goronzy JJ, )18 (W)80 (eyand CM. )18 (V)111 (asculitis in rheumatoid arthritis. Curr)]TJ
0 Tc 2.175 -1.225 Td
(Opin Rheumatol 1994;6:290-4.)Tj
-0.00011 Tc -2.175 -1.225 Td
[(47.)-875 (W)40 (inska )18 (W)40 (iloch H, )18 (Thompson HK, )37 (Y)100 (oung )55 (A, Corbett M, Shipley M,)]TJ
2.175 -1.225 Td
[(Hay F)80 (. IgA)-220 (and IgM rheumatoid factors as markers of later erosive)]TJ
0 Tc T*
(M changes in rheumatoid arthritis. Scand J Rheumatol 1998;75)Tj
0 Tw T*
(Suppl:238-43.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(48.)-875 (V)111 (an Zeben D, Hazes JMW)92 (, Zwinderman )55 (AH, Cats )55 (A, van der )18 (V)129 (oort)]TJ
0 Tc 2.175 -1.225 Td
(EAM, Breedvelt FC. Clinical significance of rheumatoid factors in)Tj
T*
[(early rheumatoid arthritis. )55 (Ann Rheum Dis 1992;51:1029-35.)]TJ
-0.00011 Tc -2.175 -1.225 Td
[(49.)-875 (V)111 (an der Zee JM, Heurkens )55 (AHM, van der )18 (V)129 (oort EAM, Daha MR,)]TJ
0 Tc 2.175 -1.225 Td
(Breedveld FC. Characterization of anti-endothelial antibodies in)Tj
T*
(patients with rheumatoid arthritis complicated by vasculitis. Clin)Tj
T*
(Exp Rheumatol 1991;9:589-94.)Tj
-0.00011 Tc -2.175 -1.225 Td
[(50.)-875 (Siegert CEH, Deha MR, van der )18 (V)129 (oort EAM, Breedveld FC. IgG)]TJ
0 Tc 2.175 -1.225 Td
[(and IgA)-220 (antibodies to the collagen-like region of C1q in rheumatoid)]TJ
T*
[(vasculitis. )55 (Arthritis Rheum 1990;33:1646-54.)]TJ
-2.175 -1.25 Td
[(51.)-875 (Coremans IEM, Hagen EC, Daha MR, et al. )55 (Antilactoferrin)]TJ
2.175 -1.25 Td
(antibodies in patient with rheumatoid arthritis are associated with)Tj
0 -1.25 TD
[(vasculitis. )55 (Arthritis Rheum 1992;35:1466-75.)]TJ
/TT1 1 Tf
10.24516 -4.81811 Td
(The Journal of Rheumatology 2001; 28:12)Tj
0 Tw -45.7952 -0.0313 Td
(2590)Tj
ET
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 576 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
54 54 m
558 54 l
S
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 576 -792 re
W n
/CS0 cs 0 0 0 0 scn
101.25 58.05 407.5 -10.84 re
f*
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 576 -792 re
W n
/CS0 CS 0 0 0 1 SCN
0.5 w
101.25 58.05 407.5 -10.84 re
S
Q
Q
q
1 0 0 1 20 0 cm
0 0 576 792 re
W n
1 0 0 1 -20 0 cm
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
122.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 504 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
119 0 obj
<>
endobj
623 0 obj
<>
endobj
91 0 obj
<>
endobj
80 0 obj
<>
endobj
79 0 obj
<>
endobj
109 0 obj
<>stream
HVpg~s""4.A\{HN*$9r"IidtjmCcmLk`VQ궶cCAꨲ8>IPΞ/O|/ 5P7Q;_1EiUΨt"#8 Ŝ1{QٞY˾ K%ۯkf3ӯZ9vM@
=؏ %(GTVg˷;3F>+_`݆-Gyg~xɄui2Z>:*s5V
jp) ~+Z>.ac!s)a>h'$6a %.(q%
Uܟ,돗
8AYoB/U2
,CnaNbՌ)&3)DǓD*